Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00051103 · ClinicalTrials.gov registry record · Phase 2
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
A Phase 2 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00051103 is a Phase 2 study that has completed, run by GlaxoSmithKline.
The verdict
NCT00051103, a Phase 2 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
The purpose of this study is to determine the efficacy of an oral investigational drug for the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.
Interventions
- DRUG Investigational Cancer Drug
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-10 |
| Est. Completion | 2005-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00051103
The ClinicalTrials.gov registry entry for NCT00051103 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Investigational Cancer Drug is the first listed.
NCT00051103 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00051103 about?
NCT00051103 is a clinical study titled "Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.". The purpose of this study is to determine the efficacy of an oral investigational drug for the treatment of metastatic breast cancer tumors that are known to overexpress HER2/neu.
What is the current status of trial NCT00051103?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-10. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00051103?
The interventions under investigation include: Investigational Cancer Drug (DRUG).
Who is sponsoring clinical trial NCT00051103?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.